XU Zhengyang,YUAN Zuguo,ZHOU Taoqi, et al. Effect of vinorelbine combined with xeloda on treating the patients with advanced breast cancer[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2014, 44(6): 441-444.
Abstract：Objective: To explore the clinical efficacy and tolerability of vinorelbine with xeloda for patients with advanced breast cancer. Methods: Forty-six patients with advanced breast cancer were enrolled in the study. All patients were given 25 mg/m2 of vinorelbine on days 1 and 8, combined with 2.0 g/m2 of xeloda daily from day 1 to 14. The combined chemotherapy was repeated every 21 days as one cycle. Patients received a maximum chemotherapy of 8 cycles or until disease progression. Results: All the 46 patients completed 225 chemotherapy cycles with a 5-cycle median. Adverse events and clinical efficacy were evaluated on all 46 patients. Complete remission (CR) in 2 patients, partial remission (PR) in 17 patients, stable disease (SD) in 17 patients, and progression of disease (PD) in 10 patients. The overall response rate (CR+PR) was 41.3%, and the disease control rates (DCR) was 78.3%. The median time to progression (TTP) was 8.3 months, 1 year and three-year survival rates were 70.6% and 27.6%.The most commonly observed adverse events were hematologic toxicity and hand-foot syndrome and angeitis. No mortality occurred during the treatment. Conclusion: Vinorelbine combined with xeloda is an effective and safe chemotherapeutic regimen for advanced breast cancer, and the adverse reactions are well tolerated.
